Bayer Pays $310M For European Rights To Heart Drug
German pharmaceutical giant Bayer and public biopharmaceutical company BridgeBio announced Monday that they would form a $310 million partnership centered on the experimental heart drug acoramidis....To view the full article, register now.
Already a subscriber? Click here to view full article